Meigabalin

Pregabalin

Central & peripheral neuropathic pain in adults including diabetic peripheral neuropathy & post-herpetic neuralgia. Generalized anxiety disorder (GAD) in adults. Management of fibromylagia. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalization.

Recommended dose: 150-600 mg daily in 2 or 3 divided doses. Neuropathic pain Initially 150 mg daily, may be increased to 300 mg daily after 3-7 days interval. Max dose: 600 mg daily after an additional 7-day interval. Epilepsy Initially 150 mg daily, may be increased to 300 mg daily after 1 wk. Max dose: 600 mg daily after an additional wk. GAD Initially 150 mg daily, may be increased to 300 mg daily after 1 wk, then 450 mg daily after an additional wk. Max dose: 600 mg daily after an additional wk. Fibromyalgia 300-450 mg daily in 2 divided doses. Initially 75 mg bid, may be increased to 150 mg bid w/in 1 wk. May further increase to 225 mg bid. Max dose: 600 mg once daily after an additional wk. Renal impairment w/ CrCl ≥60 mL/min 150 mg daily, bid or tid. Max dose: 600 mg daily, bid or tid, ≥30-<60 mL/min 75 mg daily, bid or tid. Max dose: 300 mg daily, bid or tid, ≥15-<30 mL/min 25-50 mg, once daily or bid. Max dose: 150 mg daily, once daily or bid, <15 mL/min 25 mg once daily. Max dose: 75 mg once daily. Supplementary dosage following hemodialysis 25 mg single additional dose. Max dose: 100 mg single additional dose.

May be taken with or without food.

Hypersensitivity.

Discontinue treatment immediately if angioedema symptoms eg, facial, perioral, or upper airway swelling occur. Not to be taken by patients w/ rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May cause hematologic disorder. Dizziness & somnolence; loss of consciousness, confusion, & mental impairment; transient visual blurring & other visual acuity changes. W/drawal symptoms after discontinuation. Evaluate patients for history of drug abuse & observe for signs of pregabalin misuse/abuse eg, development of tolerance, dose escalation, drug seeking behavior. Adjust hypoglycemic medications in diabetic patients who gain wt. Patients w/ severe CHF. May impair ability to drive or operate machinery. Liver & kidney disease. Women of childbearing potential must use effective contraception. Not to be used during pregnancy. Not recommended during lactation. Childn & adolescents 12-17 yr. Elderly >65 yr.

Dizziness, somnolence. Nasopharyngitis; increased appetite; euphoric mood, confusion, irritability, depression, disorientation, insomnia, decreased libido; ataxia, abnormal coordination, tremor, dysarthria, amnesia, memory impairment, attention disturbance, paraesthesia, hypoesthesia, sedation, balance disorder, lethargy; blurred vision, diplopia; vertigo; vomiting, constipation, flatulence, abdominal distension, dry mouth; muscle cramp, arthralgia, back & limb pain, cervical spasm; peripheral oedema, oedema, abnormal gait, fall, feeling drunk & abnormal fatigue; increased wt. Headache.

May potentiate effects of ethanol & lorazepam. Additive cognitive & gross motor function impairment w/ oxycodone. Resp failure & coma w/ other CNS depressants. Reduced lower GIT function (eg, intestinal obstruction, paralytic ileus, constipation) w/ medications w/ potential to produce constipation eg, opioid analgesics.

Anticonvulsants / Drugs for Neuropathic Pain

N02BF02 - pregabalin ; Belongs to the class of gabapentinoids. Used to relieve pain and other conditions.

D